3
H index
0
i10 index
19
Citations
Jeffrey Hoch : Citation Profile
University of California-Davis | RESEARCH PRODUCTION: 16 Articles 4 Chapters RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
14 years (2007 - 2021). Relations with other researchers
Works with: Authors registered in RePEc who have co-authored more than one work in the last five years with Jeffrey Hoch. | Is cited by:
| Cites to:
|
Main data
Where Jeffrey Hoch has published?
| Journals with more than one article published | # docs |
|---|---|
| PharmacoEconomics | 6 |
| PharmacoEconomics - Open | 4 |
| PLOS ONE | 2 |
Recent works citing Jeffrey Hoch (2024 and 2023)
| Year | Title of citing document |
|---|---|
| 2024 | Public preferences for the allocation of societal resources over different healthcare purposes. (2024). van Exel, Job ; Geijsen, Tom ; Boxebeld, Sander ; Mouter, Niek ; van Agthoven, Michel ; Maes, Laurence ; Makady, Amr ; Tuit, Charlotte. In: Social Science & Medicine. RePEc:eee:socmed:v:341:y:2024:i:c:s0277953623008936. Full description at Econpapers || Download paper |
| 2023 | Factors Facilitating or Creating Barriers to Returning to Work in Head and Neck Cancer Patients Within the First 6 Months After Treatment. (2023). Chang, Ya-Lan ; Cho, Kuei-An ; Chiu, Su-Erh ; Chung, Ching-Fang ; Lin, Chien-Yu ; Chen, Shu-Ching ; Huang, Bing-Shen. In: Clinical Nursing Research. RePEc:sae:clnure:v:32:y:2023:i:1:p:197-208. Full description at Econpapers || Download paper |
Works by Jeffrey Hoch:
| Year | Title | Type | Cited |
|---|---|---|---|
| 2008 | Measuring and illustrating statistical evidence in a cost-effectiveness analysis In: Journal of Health Economics. [Full Text][Citation analysis] | article | 3 |
| 2014 | Public engagement in priority-setting: Results from a pan-Canadian survey of decision-makers in cancer control In: Social Science & Medicine. [Full Text][Citation analysis] | article | 2 |
| 2021 | Labs and cases in health insurance and cost-effectiveness analyses to enhance active learning experiences in an introductory healtheconomics course for students in health professions In: Chapters. [Full Text][Citation analysis] | chapter | 0 |
| 2021 | Using net benefit regression to teach cost-effectiveness analysis with a dataset In: Chapters. [Full Text][Citation analysis] | chapter | 0 |
| In: . [Full Text][Citation analysis] | chapter | 0 | |
| 2016 | Advice about Work-Related Issues to Peers and Employers from Head and Neck Cancer Survivors In: PLOS ONE. [Full Text][Citation analysis] | article | 1 |
| 2017 | Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening In: PLOS ONE. [Full Text][Citation analysis] | article | 1 |
| 2014 | A Review and Meta-analysis of Colorectal Cancer Utilities In: Medical Decision Making. [Full Text][Citation analysis] | article | 4 |
| 2016 | Using Phase-Based Costing of Real-World Data to Inform Decision–Analytic Models for Atrial Fibrillation In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 0 |
| 2013 | Improving the Efficiency of Cost-effectiveness Analysis to Inform Policy Decisions in the Real World: Lessons from the Pharmacoeconomics Research Unit at Cancer Care Ontario In: International Series in Operations Research & Management Science. [Citation analysis] | chapter | 0 |
| 2007 | Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions In: PharmacoEconomics. [Full Text][Citation analysis] | article | 2 |
| 2013 | The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada In: PharmacoEconomics. [Full Text][Citation analysis] | article | 5 |
| 2015 | Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters In: PharmacoEconomics. [Full Text][Citation analysis] | article | 1 |
| 2015 | Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale? In: PharmacoEconomics. [Full Text][Citation analysis] | article | 0 |
| 2018 | Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment In: PharmacoEconomics. [Full Text][Citation analysis] | article | 0 |
| 2019 | A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost?Effectiveness Analysis In: PharmacoEconomics. [Full Text][Citation analysis] | article | 0 |
| 2017 | Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology In: PharmacoEconomics - Open. [Full Text][Citation analysis] | article | 0 |
| 2017 | Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR) In: PharmacoEconomics - Open. [Full Text][Citation analysis] | article | 0 |
| 2018 | The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study In: PharmacoEconomics - Open. [Full Text][Citation analysis] | article | 0 |
| 2018 | Developing Accessible, Pictorial Versions of Health-Related Quality-of-Life Instruments Suitable for Economic Evaluation: A Report of Preliminary Studies Conducted in Canada and the United Kingdom In: PharmacoEconomics - Open. [Full Text][Citation analysis] | article | 0 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated November, 3 2024. Contact: CitEc Team